Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Psychiatry and Mental Health
  •  Orthopedic Surgery
  •  Neurology
  •  Dermatology and Cosmetology
  •  Nursing
  •  Hematology
  •  Emergency Medicine and Critical Care
  •  Lung Cancer


Citation: Ann Clin Case Rep. 2022;7(1):2210.DOI: 10.25107/2474-1655.2210

The Use of Totally Implanted Vascular Access Devices (Ports) in the Treatment of Atypical Hemolytic Uremic Syndrome in Children

Magdalena Mróz1, Katarzyna Krzyżak1, Anna Bogdał2, Hanna Woźny1, Martyna Bik1, Elżbieta Trembecka-Dubel3, Dagmara Roszkowska-Bjanid3, Maria Szczepańska1*

1Department of Pediatrics, Medical University of Silesia in Katowice, Poland 2District Hospital in Zawiercie, Poland 3Department of Pediatric Nephrology with Dialysis Division for Children, Public Clinical Hospital No. 1, Poland

*Correspondance to: Maria Szczepańska 

 PDF  Full Text Case Series | Open Access


Totally Implanted Vascular Access devices (Ports; TIVAPs) are commonly used in oncological treatment in children. They are important for long-term therapy requiring continuous vascular access. The use of central catheters may also be extremely helpful in the therapy of children with chronic kidney diseases, such as atypical Hemolytic Uremic Syndrome (aHUS). In the past, the treatment of this syndrome required regular supplementation of fresh frozen plasma in the chronic phase of the disease, or substitution of red blood cells during relapse and plasmapheresis application. Eculizumab registered worldwide for the treatment of aHUS is injected intravenously every 2 weeks. The manuscript presents a retrospective evaluation of the use of TIVAPs in 4 children treated due to aHUS. A total number of 6 ports was used, each 4.3 ± 1.7 years of duration on average. Ten complications were reported, 30% of which included staphylococcal infections. Infections with encapsulated organisms were not recorded. Conclusion: The use of vascular ports in children with aHUS seems to be safe provided that close monitoring and early detection of complications are carried out, allows to maintain repeated painless long-term access to the venous system, make available vascular preservation in patients with a significant risk for end-stage kidney disease.


Totally Implanted Vascular Access devices (ports; TIVAPs); Atypical hemolyticuremic syndrome; TIVAPs complications; Eculizumab

Cite the Article:

Mróz M, Krzyżak K, Bogdał A, Woźny H, Bik M, Trembecka-Dubel E, et al. The Use of Totally Implanted Vascular Access Devices (Ports) in the Treatment of Atypical Hemolytic Uremic Syndrome in Children. Ann Clin Case Rep. 2022; 7: 2210..

Search Our Journal

Journal Indexed In

Articles in PubMed

Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and other Naturally Occurring Compounds, Part I
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Acute Monocytic Leukemia Secondary to Angioimmunoblastic T-Cell Lymphoma: A Case Report and Literature Review
 Abstract  PDF  Full Text
Development and Validation of a Nomogram for Predicting Bladder Calculi Risk in Patients with Benign Prostatic Hyperplasia
 Abstract  PDF  Full Text
View More...